Serum Human Leukocyte Antigen-G and Soluble Interleukin 2 Receptor Levels in Acute Lymphoblastic Leukemic Pediatric Patients

Abstract

Aims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in the proliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidenced in different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyte antigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosis and follow up of acute lymphoblastic leukemia (ALL). Subjects and Methods: Both markers were determined by ELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapy as well as in the serum of 14 healthy donors that were selected as a control group. Results: ALL patients showed abnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, there was a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However, after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand, serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy, sIL-2R decreased significantly compared with before treatment. Conclusions: From these results it could be suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in pediatric patients.Keywords: Soluble human leukocyte antigen-G -soluble interleukin-2 receptor -acute lymphoblastic leukemia

Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment

“…All these results suggest that H2S and cytokines are involved in immune regulatory process of children with ALL with chemotherapy, which is consistent with this report. Motowi et al [ 17 ] suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in paediatric patients. Research carried out in order to search for new more effective treatments for patients with ALL, seems inclined to use the immune response factors, such as NK in the presence of clinical grade IL-2 and IL-15 [ 18 ].…”

Going back to class I: MHC and immunotherapies for childhood cancer

“…The majority of ALL cases have class I MHC expression . In addition, non‐classical HLA‐G was up‐regulated after chemotherapy treatment . No significant differences in MHC class I expression were seen between diagnostic and relapsed samples in pre‐B ALL .…”

“…The majority of ALL cases have class I MHC expression . In addition, non‐classical HLA‐G was up‐regulated after chemotherapy treatment .…”